179246-44-7Relevant articles and documents
Methods for detecting and reducing impurities of Lapatinib and salts thereof
-
Page/Page column 11-12, (2015/02/18)
Impurities of lapatinib such as N-{3-chloro-4-[(2-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazoline-4-amine compound of formula (I) or a salt thereof: and analytical methods for identifying and quantifying such impurities of Lapatinib and salts thereof are provided. Also provided is Lapatinib containing less than about 0.05 percent of this and related impurities and methods for preparing such pure forms of Lapatinib.
Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis
Patel, Gautam,Karver, Caitlin E.,Behera, Ranjan,Guyett, Paul J.,Sullenberger, Catherine,Edwards, Peter,Roncal, Norma E.,Mensa-Wilmot, Kojo,Pollastri, Michael P.
, p. 3820 - 3832 (2013/06/27)
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b
Impurity of lapatinib and salts thereof
-
Page/Page column 9; 10, (2012/09/10)
The present invention regards an impurity of lapatinib, N-{3-chloro-4-[(2-fluorobynzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl] quinazoline-4-amine compound of formula (I) or a salt thereof: the analytical methods for identifying it and quantifying it in Lapatinib and salts thereof. The invention also regards Lapatinib comprising less than 0.05 percent of this impurity and the relative method of preparation.
